Kiniksa Hits All-Time High on Raised Revenue Outlook, Leading Biotech Gainers

Earnings

โดย RTTNews·Read original

Summary · why it matters

Kiniksa Pharmaceuticals touched an all-time high after raising its full-year revenue outlook on strong Arcalyst sales, leading a session of sharp biotech gains. Arcalyst generated $243.6 million in net product revenue in the second quarter of 2026, up about 55% year-over-year, prompting the company to lift its full-year 2026 net product revenue guidance to $980 million to $995 million from a prior forecast of $930 million to $945 million. Trinity Biotech surged over 36% after announcing clinical results for its CGM+ wearable biosensor and completing a one-for-thirty reverse ADS split to regain Nasdaq compliance. OPKO Health jumped more than 33% despite issuing softer third-quarter guidance, as it reported second-quarter revenue of $163.5 million and highlighted progress across multiple early-stage pipeline programs. MapLight Therapeutics rebounded over 24% from a prior-day selloff triggered by mixed Phase 2 schizophrenia trial results, with the company planning an End-of-Phase 2 meeting with the FDA. ProMIS Neurosciences rallied more than 23% after reporting positive blinded six-month interim safety and biomarker data for PMN310 in Alzheimer's disease, and Prelude Therapeutics gained over 19% on no specific news.